Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance
- PMID: 11905724
- DOI: 10.1016/S1470-2045(01)00454-5
Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance
Abstract
Drugs that produce DNA interstrand crosslinks (ICLs), between the two complementary strands of the double helix, have an important role in chemotherapy regimens for cancer. Novel crosslinking agents, and targeting strategies involving DNA crosslinking agents, continue to be developed. The ability of cells to repair DNA ICLs is a critical determinant of sensitivity, and recent dinical studies indicate that DNA repair capacity is strongly implicated in both inherent tumour sensitivity and acquired drug resistance. A detailed understanding of the cellular mechanisms that act to eliminate these critical DNA lesions is clearly important. DNA ICLs present a complex challenge to DNA repair mechanisms because of the involvement of both DNA strands. It is now clear that cells from bacteria and yeast to mammals eliminate interstrand ICLs through the coordinated action of several DNA repair pathways. Recently, a model of ICL repair has been proposed, in which mammalian cells use novel excision repair reactions (requiring the XPF and ERCC1 proteins) to uncouple the crosslink. This is followed by a homologous recombination step to provide the genetic information needed to complete repair. This new knowledge may permit the development of screens for tumour response to crosslinking agents, and should also aid the design of more effective crosslinking agents that evade DNA repair. In addition, the proteins mediating the repair reactions represent potential targets for therapeutic intervention.
Similar articles
-
Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair.Environ Mol Mutagen. 2010 Jul;51(6):567-81. doi: 10.1002/em.20583. Environ Mol Mutagen. 2010. PMID: 20658648 Review.
-
Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?Trends Genet. 2008 Feb;24(2):70-6. doi: 10.1016/j.tig.2007.11.003. Epub 2008 Jan 14. Trends Genet. 2008. PMID: 18192062 Review.
-
Strategies for DNA interstrand crosslink repair: insights from worms, flies, frogs, and slime molds.Environ Mol Mutagen. 2010 Jul;51(6):646-58. doi: 10.1002/em.20551. Environ Mol Mutagen. 2010. PMID: 20143343 Review.
-
The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy.Anticancer Agents Med Chem. 2015;16(2):221-46. doi: 10.2174/1871520615666150824160421. Anticancer Agents Med Chem. 2015. PMID: 26299659 Review.
-
DNA interstrand crosslinks induce a potent replication block followed by formation and repair of double strand breaks in intact mammalian cells.DNA Repair (Amst). 2012 Dec 1;11(12):976-85. doi: 10.1016/j.dnarep.2012.09.010. Epub 2012 Oct 23. DNA Repair (Amst). 2012. PMID: 23099010
Cited by
-
(5'S) 5',8-Cyclo-2'-Deoxyadenosine Cannot Stop BER. Clustered DNA Lesion Studies.Int J Mol Sci. 2021 May 31;22(11):5934. doi: 10.3390/ijms22115934. Int J Mol Sci. 2021. PMID: 34072994 Free PMC article.
-
Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases.J Biol Chem. 2012 Jul 27;287(31):26254-67. doi: 10.1074/jbc.M112.367243. Epub 2012 Jun 11. J Biol Chem. 2012. PMID: 22692201 Free PMC article.
-
Fanconi-like crosslink repair in yeast.Genome Integr. 2012 Oct 12;3(1):7. doi: 10.1186/2041-9414-3-7. Genome Integr. 2012. PMID: 23062727 Free PMC article.
-
Initiation of DNA interstrand cross-link repair in mammalian cells.Environ Mol Mutagen. 2010 Jul;51(6):604-24. doi: 10.1002/em.20559. Environ Mol Mutagen. 2010. PMID: 20658650 Free PMC article. Review.
-
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.Clin Cancer Res. 2010 Jan 1;16(1):99-108. doi: 10.1158/1078-0432.CCR-09-2434. Epub 2009 Dec 15. Clin Cancer Res. 2010. PMID: 20008842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources